Literature DB >> 18651468

Myocardial contractility improvement after coronary artery by-pass grafting in a 1-year observation: The role of myocardial viability assessment.

Małgorzata Knapp, Włodzimierz J Musiał, Anna Lisowska, Tomasz Hinrle.   

Abstract

BACKGROUND: Left ventricular (LV) contractility impairment in coronary artery disease patients may be the effect of heart muscle hibernation due to chronic ischemia. Revascularization is the only method to restore contractile function in these patients. The time and degree of LV function improvement have not been precisely determined, and the published data are discordant. The aim of our study was to evaluate the time of myocardial contractility recovery after surgical revascularization in patients with systolic LV dysfunction in relation to the results of echocardiography stress tests.
METHODS: The study included 50 patients with multivessel coronary artery disease and decreased left ventricular ejection fraction (LVEF < 40%) qualified for coronary artery by-pass grafting. The intervention was preceded by rest echocardiography, low dose dobutamine stress test (5-10 microg/kg/min) and by low dose dipyridamole stress test (0.24 mg/kg during 4 min) performed on the next day. Consecutive rest echocardiograms were performed immediately after the intervention and after 3, 6 and 12 months. LVEF and the index of left ventricular contractility (WMSI, wall motion score index) were evaluated at each examination.
RESULTS: During 1-year follow-up after coronary artery by-pass grafting (CABG), significant improvement in LV systolic function was observed (LVEF increased, WSMI reduced), with major changes occurring over the first 6 months. The correlation of echocardiography parameters (EF, WMSI) at stress tests and during 1-year follow-up showed that the strongest relationship exists between the change in WMSI both in dobutamine and dipyridamole stress tests and the improvement in WMSI observed after 6 months.
CONCLUSIONS: LV function improvement after CABG in patients with systolic LV dysfunction was most pronounced 3 to 6 months after the intervention. Both types of stress tests are characterized by similar diagnostic value for assessing LV myocardial viability. WMSI calculated during stress was identified to have the strongest prognostic value. (Cardiol J 2007; 14: 246-251).

Entities:  

Year:  2007        PMID: 18651468

Source DB:  PubMed          Journal:  Cardiol J        ISSN: 1898-018X            Impact factor:   2.737


  5 in total

1.  Multiple coronary stenting negatively affects myocardial recovery after coronary bypass grafting.

Authors:  Shin Yajima; Daisuke Yoshioka; Satsuki Fukushima; Koichi Toda; Shigeru Miyagawa; Yasushi Yoshikawa; Hiroki Hata; Shunsuke Saito; Keitaro Domae; Yoshiki Sawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-05-14

2.  Systolic heart function remains depressed for at least 30 days after on-pump cardiac surgery.

Authors:  Peter Juhl-Olsen; Rajesh Bhavsar; Christian Alcaraz Frederiksen; Erik Sloth; Carl-Johan Jakobsen
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-06-08

3.  Echocardiographic Evaluation of the Effects of a Single Bolus of Erythropoietin on Reducing Ischemia-Reperfusion Injuries during Coronary Artery Bypass Graft Surgery; A Randomized, Double-Blind, Placebo-Control Study.

Authors:  Shervin Ziabakhsh-Tabary; Rozita Jalalian; Farzad Mokhtari-Esbuie; Mohammad Reza Habibi
Journal:  Iran J Med Sci       Date:  2014-03

4.  Clinical utility of early postoperative cardiac multidetector computed tomography after coronary artery bypass grafting.

Authors:  Doo Kyoung Kang; Sang Hyun Lim; Jin Sun Park; Joo Sung Sun; Taeyang Ha; Tae Hee Kim
Journal:  Sci Rep       Date:  2020-06-08       Impact factor: 4.379

5.  Left ventricular function outcome after coronary artery bypass grafting, King Abdullah Medical City (KAMC)- single-center experience.

Authors:  Sheeren Khaled; Ehab Kasem; Ahmed Fadel; Yusuf Alzahrani; Khadijah Banjar; Wafa'a Al-Zahrani; Hajar Alsulami; Mazad Ali Allhyani
Journal:  Egypt Heart J       Date:  2019-08-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.